SEC Form 4 · accession 0001140361-17-010774
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rebecca M Henderson
Director
Period of report
Feb 28, 2017
Accepted (ET)
Mar 6, 2017 · 6:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 28, 2017 | S | 700 | $144.5042 | D | 20,750 | D | |
| Common StockF2 | Feb 28, 2017 | S | 5,500 | $145.2305 | D | 15,250 | D | |
| Common StockF3 | Feb 28, 2017 | S | 300 | $146.00 | D | 14,950 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average sales price of the shares sold ranging from a low of $143.88 to a high of $144.87 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F2Represents the weighted average sales price of the shares sold ranging from a low of $144.91 to a high of $145.91 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average sales price of the shares sold ranging from a low of $145.95 to a high of $146.14 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.